🇺🇸 Lidocaine Hydrochloride with Epinephrine in United States

31 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 6 reports (19.35%)
  2. Haemorrhage — 6 reports (19.35%)
  3. Aphasia — 5 reports (16.13%)
  4. Dizziness — 5 reports (16.13%)
  5. Expired Product Administered — 4 reports (12.9%)
  6. Blindness — 1 report (3.23%)
  7. Chest Pain — 1 report (3.23%)
  8. Coma — 1 report (3.23%)
  9. Discomfort — 1 report (3.23%)
  10. Erythema — 1 report (3.23%)

Source database →

Lidocaine Hydrochloride with Epinephrine in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Lidocaine Hydrochloride with Epinephrine approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Lidocaine Hydrochloride with Epinephrine in United States?

NYU Langone Health is the originator. The local marketing authorisation holder may differ — check the official source linked above.